Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-307: tarlatamab in Chinese patients with advanced small cell lung cancer after at least two prior lines
CTR20242298Phase 2Active
- Sponsor
- Amgen
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Aug 2024; status: active.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20242298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242298.